The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy
Open accessAbstract
The poor prognosis of patients with aggressive and invasive cancers combined with toxic effects and short half-life of currently available treatments necessitate development of more effective tumor selective therapies. Mesenchymal stem cells (MSCs) are emerging as novel cell-based delivery agents; however, a thorough investigation addressing their therapeutic potential and fate in different cancer models is lacking. In this study, we explored the engineering potential, fate, and therapeutic efficacy of human MSCs in a highly malignant and invasive model of glioblastoma. We show that engineered MSC retain their “stem-like” properties, survive longer in mice with gliomas than in the normal brain, and migrate extensively toward gliomas. We also show that MSCs are resistant to the cytokine tumor necrosis factor apoptosis ligand (TRAIL) and, when engineered to express secreted recombinant TRAIL, induce caspase-mediated apoptosis in established glioma cell lines as well as CD133-positive primary glioma cells in vitro. Using highly malignant and invasive human glioma models and employing real-time imaging with correlative neuropathology, we demonstrate that MSC-delivered recombinant TRAIL has profound anti-tumor effects in vivo. This study demonstrates the efficacy of diagnostic and therapeutic MSC in preclinical glioma models and forms the basis for developing stem cell-based therapies for different cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pluripotency of mesenchymal stem cells derived from adult marrow
Jiang, Y., Jahagirdar, B. N., Reinhardt, R. L., Schwartz, R. E., Keene, C. D., Ortiz-Gonzalez, X. R., Reyes, M., Lenvik, T., Lund, T., Blackstad, M., et al. (2002) · Nature · doi:10.1038/nature00870 · Cited by 5,518
RetractedIdentification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
A Perivascular Niche for Brain Tumor Stem Cells
Calabrese, C., Poppleton, H., Kocak, M., Hogg, T. L., Fuller, C., Hamner, B., Oh, E. Y., Gaber, M. W., Finklestein, D., Allen, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.020 · Cited by 2,197
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Imitola, J., Raddassi, K., Park, K. I., Mueller, F.-J., Nieto, M., Teng, Y. D., Frenkel, D., Li, J., Sidman, R. L., Walsh, C. A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408258102 · Cited by 1,057
Human Bone Marrow–Derived Mesenchymal Stem Cells in the Treatment of Gliomas
Nakamizo, A., Marini, F., Amano, T., Khan, A., Studeny, M., Gumin, J., Chen, J., Hentschel, S., Vecil, G., Dembinski, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1874 · Cited by 1,035
Son, B., Marquez‐Curtis, L. A., Kucia, M., Wysoczynski, M., Turner, A. R., Ratajczak, J., Ratajczak, M. Z., & Janowska‐Wieczorek, A. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0271 · Cited by 641
Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model
Nakamura, K., Ito, Y., Kawano, Y., Kurozumi, K., Kobune, M., Tsuda, H., Bizen, A., Honmou, O., Niitsu, Y., & Hamada, H. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302276 · Cited by 597
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
Almasan, A., & Ashkenazi, A. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00029-7 · Cited by 553
Research works printed but not linked: 4
- 10.1038/sj.mt.6300155 · doi:10.1038/sj.mt.6300155
- 10.1006/excr.1999.4760 · doi:10.1006/excr.1999.4760
- M Ehtesham, et al., Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 62, 7170–7174 (2002).
- 10.3171/jns.2006.105.1.88 · doi:10.3171/jns.2006.105.1.88
Cited by
Lee, R. H., Pulin, A. A., Seo, M. J., Kota, D. J., Ylostalo, J., Larson, B. L., Semprun-Prieto, L., Delafontaine, P., & Prockop, D. J. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.05.003 · Cited by 1,898
“…n = 3 or 4 mice in each group; ***p < 0.0001 compared to MI controls; N.S., not significant compared to MI controls; *p < 0.05 for MI + MSCs versus MI + rhTSG-6. lez-Rey et al., 2009; Sasportas et al., 2009), apparently because of the immune modulatory effects of the cells (Uccelli et al., 2008).”
InfluentialMesenchymal Stem Cells as Therapeutics
Parekkadan, B., & Milwid, J. M. (2010) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-070909-105309 · Cited by 759
Shattering barriers toward clinically meaningful MSC therapies
Levy, O., Kuai, R., Siren, E. M. J., Bhere, D., Milton, Y., Nissar, N., De Biasio, M., Heinelt, M., Reeve, B., Abdi, R., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba6884 · Cited by 694
Self-citationMesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy
Baglio, S. R., Pegtel, D. M., & Baldini, N. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00359 · Cited by 542
Molecular Basis for the Regulation of Angiogenesis by Thrombospondin-1 and -2
Lawler, P. R., & Lawler, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006627 · Cited by 532
“Recently, mesenchymal stem cells (MSCs) have emerged as novel cell-based delivery agents to achieve these ends (Aboody et al. 2008; Sasportas et al. 2009), and data from TSP-expressing cell lines in central nervous system gliomas are encouraging.”
BackgroundKievit, F. M., & Zhang, M. (2011) · Advanced Materials · doi:10.1002/adma.201102313 · Cited by 496
Cell or Cell Membrane-Based Drug Delivery Systems
Tan, S., Wu, T., Zhang, D., & Zhang, Z. (2015) · Theranostics · doi:10.7150/thno.11852 · Cited by 466
Skin cancer and new treatment perspectives: A review
Simões, M. C. F., Sousa, J. J. S., & Pais, A. A. C. C. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.11.001 · Cited by 414
Bone marrow-derived mesenchymal stem cells and the tumor microenvironment
Bergfeld, S. A., & DeClerck, Y. A. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9222-7 · Cited by 345
Mesenchymal stem cells engineered for cancer therapy
Shah, K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.010 · Cited by 322
Self-citationReciprocal regulation of mesenchymal stem cells and immune responses
Wang, Y., Fang, J., Liu, B., Shao, C., & Shi, Y. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.10.001 · Cited by 311
The neurobiology of gliomas: from cell biology to the development of therapeutic approaches
Westphal, M., & Lamszus, K. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3060 · Cited by 286
TRAIL on trial: preclinical advances in cancer therapy
Stuckey, D. W., & Shah, K. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.08.007 · Cited by 276
Self-citationZhuang, W.-Z., Lin, Y.-H., Su, L.-J., Wu, M.-S., Jeng, H.-Y., Chang, H.-C., Huang, Y.-H., & Ling, T.-Y. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00725-7 · Cited by 258
Guided by the light: visualizing biomolecular processes in living animals with bioluminescence
Prescher, J. A., & Contag, C. H. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.11.001 · Cited by 255
Non-genetic engineering of cells for drug delivery and cell-based therapy
Wang, Q., Cheng, H., Peng, H., Zhou, H., Li, P. Y., & Langer, R. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.12.003 · Cited by 225
Mesenchymal stem cell secretome and regenerative therapy after cancer
Zimmerlin, L., Park, T. S., Zambidis, E. T., Donnenberg, V. S., & Donnenberg, A. D. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.010 · Cited by 168
Galland, S., & Stamenkovic, I. (2020) · The Journal of Pathology · doi:10.1002/path.5357 · Cited by 165
Wang, L. L., Janes, M. E., Kumbhojkar, N., Kapate, N., Clegg, J. R., Prakash, S., Heavey, M. K., Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10214 · Cited by 162
Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review
Christodoulou, I., Goulielmaki, M., Devetzi, M., Panagiotidis, M., Koliakos, G., & Zoumpourlis, V. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-1078-8 · Cited by 122
Stem cells as vectors for antitumour therapy
Loebinger, M. R., & Janes, S. M. (2010) · Thorax · doi:10.1136/thx.2009.128025 · Cited by 109
Xu, S., Menu, E., Becker, A. D., Van Camp, B., Vanderkerken, K., & Van Riet, I. (2012) · Stem Cells · doi:10.1002/stem.787 · Cited by 103
Potential implications of mesenchymal stem cells in cancer therapy
Dai, L.-J., Moniri, M. R., Zeng, Z.-R., Zhou, J. X., Rayat, J., & Warnock, G. L. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.02.012 · Cited by 99
Ramamonjisoa, N., & Ackerstaff, E. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00003 · Cited by 93
“The preferential accumulation of MSCs at sites of inflammation and tumors makes them an ideal vehicle for treatment delivery (155, 181, 182), and combined treatment/imaging MSC moieties are being developed for cell tracking and treatment monitoring (175, 177, 178, 183).”
BackgroundMesenchymal stem cells and cancer: Friends or enemies?
Hong, I.-S., Lee, H.-Y., & Kang, K.-S. (2014) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2014.01.006 · Cited by 82
Mesenchymal stromal cells as cancer promoters
Antoon, R., Overdevest, N., Saleh, A. H., & Keating, A. (2024) · Oncogene · doi:10.1038/s41388-024-03183-1 · Cited by 75
New perspective into mesenchymal stem cells: Molecular mechanisms regulating osteosarcoma
Chang, X., Ma, Z., Zhu, G., Lu, Y., & Yang, J. (2021) · Journal of Bone Oncology · doi:10.1016/j.jbo.2021.100372 · Cited by 70
Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells
Norozi, F., Ahmadzadeh, A., Shahrabi, S., Vosoughi, T., & Saki, N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5187-7 · Cited by 69
Rossignoli, F., Spano, C., Grisendi, G., Foppiani, E. M., Golinelli, G., Mastrolia, I., Bestagno, M., Candini, O., Petrachi, T., Recchia, A., et al. (2019) · Theranostics · doi:10.7150/thno.27576 · Cited by 55
Drug-releasing mesenchymal cells strongly suppress B16 lung metastasis in a syngeneic murine model
Pessina, A., Leonetti, C., Artuso, S., Benetti, A., Dessy, E., Pascucci, L., Passeri, D., Orlandi, A., Berenzi, A., Bonomi, A., et al. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0200-3 · Cited by 39
“Although the presence of some conflicting data [52, 53], in general preclinical studies indicate that MSCs loaded with anti-cancer molecules could be very effective to inhibit primary and metastatic cancer growth [3–6].”
BackgroundGuiho, R., Biteau, K., Grisendi, G., Taurelle, J., Chatelais, M., Gantier, M., Heymann, D., Dominici, M., & Redini, F. (2016) · International Journal of Cancer · doi:10.1002/ijc.30402 · Cited by 38
The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics
Tang, J., Chen, Y., Wang, C., Xia, Y., Yu, T., Tang, M., Meng, K., Yin, L., Yang, Y., Shen, L., et al. (2024) · MedComm · doi:10.1002/mco2.663 · Cited by 31
The role of mesenchymal stem cells in oncology and regenerative medicine
Maliha, K., Syeda Ezze Rukhshan, A., & Amanda L, O. (2017) · Future Oncology · doi:10.2217/fon-2016-0264 · Cited by 5
Metadata
- Authors
- Sasportas, L. S., Kasmieh, R., Wakimoto, H., Hingtgen, S., van de Water, J. A. J. M., Mohapatra, G., Figueiredo, J. L., Martuza, R. L., Weissleder, R., & Shah, K.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-03-24
- Volume
- 106
- Issue
- 12
- Pages
- 4822-4827
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2000534793
- Cited by
- 455
- References
- 45
- FWCI
- 17.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.